BNTX Stock BioNTech SE

$80.96
1d-0.52%5d-5.42%1m-11.32%ytd-14.96%
At close · Nov 20, 4:00 PM ET
After hours $81.00 +0.05% · Nov 20, 7:25 PM ET
52w low $79.523% of range$124 52w high
Price

Today’s call · BNTX

All live ideas →

6 of 6 technical checks lean bearish

BNTX is in a downtrend, momentum soft. $84.91 is the level overhead; $80 the first support below.

No open idea.From $80.96 the reward-to-risk to $80 against $84.91 is 0.2 — below the 3:1 bar.
What would create one:
  • A close below $80 on rising volume (breakdown).
  • A bounce to $84.91 that fails (entry near resistance).
Alert me at a level

The brief

Price vs 50-day · belowPrice vs 200-day · below50d vs 200d avg · belowMACD · bearishRSI momentum · 315-day tape · -5.4%
signalBNTX’s 50-day average is below the 200-day — long-term trend alignment is bearish.
levelFirst support $80.0 is 1.19% below.
volumeVolume is expanding vs its 20-day average.
newsModerna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027
All readings
TrendDowntrend · below 50-day & below 200-day
MomentumRSI 31.5 · MACD bearish
Trend strengthADX 19.1 · weak or range
Location-11.5% vs 50-day MA
52-week range-32% from high · +0% from low
VolatilityATR 2.68 · ~3.3%/day
RSI 14
31.5
MACD
-2.50
ADX 14
19.1
ATR 14
2.68
SMA 50
$91.52
SMA 200
$95.09

Levels that matter

$84.91swing zone · 3×+4.9%
$88.13swing zone · 6×+8.9%
$90round+11.2%
$80round−1.2%
$70round−13.5%

Compare with…

Analyst overview · Nov 21

BioNTech SE (BNTX) under pressure, downtrend likely persists

BioNTech SE closed at $80.96 on November 20, slipping another half percent as the daily move followed a broader weekly decline. The price now sits at the low end of its 52‑week range and below both the 50‑day and 200‑day moving averages, reinforcing a bearish outlook for the next two to six weeks. The balance of evidence points to further downside, with a breakout math that targets $70 and a stop near $85.58.

Why it matters

The recent slide reflects a continuation of a downtrend that began after the stock peaked at $91.29 on October 21, a drop of roughly 11 % from that high. The market has priced in a weaker outlook for the biotech sector, as shown by the Healthcare Select Sector SPDR (XLV) losing 6.15 % over the past five days while the S&P 500 fell 8.56 % in the same period. BNTX’s own five‑day decline of 5.42 % is modest relative to its peers, indicating that the stock is lagging both the broader market (‑2.5 % versus SPY over 50 days) and its sector (‑12.2 % versus XLV over 50 days). This lag suggests that sellers are still in control and that the recent move is not solely a market‑wide correction.

Analyst consensus remains a “buy” with an average price target of $112.14, but that target sits 27.8 % above the current price, implying a wide valuation gap. The low‑end target of $74.32 is only marginally below today’s level, highlighting the spread of expectations. The consensus does not appear to have shifted dramatically despite the price action, indicating that the bullish narrative is still present but is outweighed by technical weakness.

The debate among market participants centers on whether the stock’s oversold RSI of 31.5 signals a bottom or merely a continuation of weakness. Some argue that the swing‑zone resistance at $84.91, where sellers have previously stepped in, will hold, while others point to the round $80 support as a potential floor. No new catalyst has emerged; the next earnings report is scheduled for November 3, 2026, and no material news has been released since the October peak.

In the absence of fresh fundamentals, the price action is driven largely by technical factors and sector momentum. The volume on the day was 64.3 % of the 20‑day average, indicating relatively light participation and a lack of conviction among buyers.

What the evidence says

Long‑term, the thesis that BNTX is in a downtrend remains intact. The stock trades below its 40‑week average, its 52‑week low is the current price, and both the 50‑day SMA ($91.52) and 200‑day SMA ($95.09) sit well above the market. The RSI is near the oversold region, but that alone does not overturn the prevailing bearish structure.

For the next two to six weeks, the balance of evidence leans negative with high conviction. The daily trend aligns with the weekly downtrend, the stock is lagging the S&P 500 by 2.5 % over 50 days and lagging XLV by 12.2 % over the same horizon, and the breakout math points to a downside target of $70. The conviction points (three of four) are satisfied by the trend alignment, lagging performance, and the swing‑zone hold. The strongest counter‑argument is the consensus “buy” rating and a mean target of $112.14, which suggests upside potential if fundamentals improve. However, that optimism is not reflected in price action, and the technical picture remains dominant, limiting the conviction from reaching a perfect score.

Levels that matter

The structure holds the price above the swing‑zone level of $84.91, a zone where sellers have repeatedly taken control on rallies. A close above $88.13, another swing‑zone resistance, would be required to signal that the weekly downtrend may be ending. Until then, the downtrend is expected to persist.

The breakout math defines a downside breakout as a daily close below the round $80 level. The stop is set at $85.58, derived from $84.91 plus a quarter of the 14‑day ATR ($2.68). The target is $70, a round figure that yields a reward‑to‑risk of 1.8. Because the math does not achieve a 3‑to‑1 ratio, a price move to roughly $66 would be needed to meet that threshold.

What would change the picture

A weekly close above $88.13 would alter the current narrative, indicating that the weekly downtrend may be weakening. The non‑price factor that could trigger such a shift is a materially better-than‑expected earnings report on November 3, 2026, especially if revenue or pipeline milestones exceed consensus expectations.

What to watch

  • November 3, 2026 earnings – focus on the headline earnings per share and any updates to the mRNA pipeline.
  • Sector moves – any significant news affecting XLV, such as FDA approvals or major biotech mergers, could sway BNTX.
  • Valuation – the gap between the current price and the consensus mean target of $112.14 remains wide; a narrowing of that spread would be notable.

MarketCrew is AI-powered and can make mistakes — double-check before acting. Informational only, not investment advice.